hn.today

PVX-001: open-source Covid-19 vaccine starts Phase 1 trial

chronicles.popvax.com103 points17 comments
Screenshot of PVX-001: open-source Covid-19 vaccine starts Phase 1 trial

PopVax has initiated a first-in-human Phase I trial of PVX-001, a broadly protective COVID-19 vaccine, with the first two participants dosed in Melbourne on August 31, 2026; the trial will enroll 36 healthy adults, and 14 participants had been dosed by October 6 with no serious adverse events reported. PVX-001 uses mRNA that instructs cells to produce a self-assembling virus-like particle (VLP) displaying an engineered SARS-CoV-2 receptor-binding domain (RBD). In mice this RNA-encoded VLP approach yielded over 50-fold higher neutralizing antibody titers versus the same immunogen without VLP display and over 20-fold higher titers versus a first-generation FDA-approved mRNA vaccine at the same dose, with demonstrated neutralization of Gamma, Lambda and Omicron BA.1 variants.

The program embodies a full-stack build: an in-house computational design pipeline, a fridge-stable lipid nanoparticle formulation based on the novel ionizable lipid PVXL-150 that allows 2-8 °C storage for at least nine months, and end-to-end GMP-capable manufacturing at an RNA Foundry in Hyderabad that can produce up to one million doses per year. Development was funded and supported by multiple global partners including Gates Foundation, Balvi, Good Ventures and NIAID Project NextGen; doses were vialed in the U.S. and shipped to Australia. After Phase I concludes, PopVax will open-source the vaccine design and waive enforcement of IP against use for any betacoronavirus, aiming to accelerate broadly protective, deployable vaccines and other pipeline programs.

Read on chronicles.popvax.com17 comments on Hacker News

Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.

More in Science

The daily digest

Today's best Hacker News stories, summarized and screenshotted, one email a day.